Nanoparticulate carrier(s): an emerging paradigm in new generation vaccine development
Nanostructures for Drug Delivery, Page: 523-550
2017
- 3Citations
- 19Captures
Metric Options: CountsSelecting the 1-year or 3-year option will change the metrics count to percentiles, illustrating how an article or review compares to other articles or reviews within the selected time period in the same journal. Selecting the 1-year option compares the metrics against other articles/reviews that were also published in the same calendar year. Selecting the 3-year option compares the metrics against other articles/reviews that were also published in the same calendar year plus the two years prior.
Example: if you select the 1-year option for an article published in 2019 and a metric category shows 90%, that means that the article or review is performing better than 90% of the other articles/reviews published in that journal in 2019. If you select the 3-year option for the same article published in 2019 and the metric category shows 90%, that means that the article or review is performing better than 90% of the other articles/reviews published in that journal in 2019, 2018 and 2017.
Citation Benchmarking is provided by Scopus and SciVal and is different from the metrics context provided by PlumX Metrics.
Example: if you select the 1-year option for an article published in 2019 and a metric category shows 90%, that means that the article or review is performing better than 90% of the other articles/reviews published in that journal in 2019. If you select the 3-year option for the same article published in 2019 and the metric category shows 90%, that means that the article or review is performing better than 90% of the other articles/reviews published in that journal in 2019, 2018 and 2017.
Citation Benchmarking is provided by Scopus and SciVal and is different from the metrics context provided by PlumX Metrics.
Book Chapter Description
Vaccination has been accomplished as one of the most effective method of regulating microbial infections. Progress in nano-biotechnology has created opportunities for the development of a nanocarrier-based new generation of vaccines against various diseases such as cancer, malaria, hepatitis B, anthrax, AIDS, etc. Nanoparticulate-carrier-based vaccine delivery is a promising approach owing to their nano size, biodegradability, biocompatibility nature, immune adjuvant property, spatiotemporal delivery of antigens, and ability to provide effective immunization through better targeting and by triggering antibody response at the cellular level. Nanoparticulate carriers can overcome the major challenges associated with conventional vaccines such as stability, low immune response, biocompatibility, degradation followed by clearance from the site sometimes prior to the desired action. Nanocarriers include polymeric nanoparticles, liposomes, niosomes, bilosomes, emulsomes, nanocapsules, and so forth progressively being applied for effective nanovaccines development. The proposed chapter summarizes the cutting edge technologies of nanoparticulate-carrier-based new generation of vaccine development, including design aspects, clinical trials, and so on.
Bibliographic Details
http://www.sciencedirect.com/science/article/pii/B9780323461436000178; http://dx.doi.org/10.1016/b978-0-323-46143-6.00017-8; http://www.scopus.com/inward/record.url?partnerID=HzOxMe3b&scp=85088104985&origin=inward; https://linkinghub.elsevier.com/retrieve/pii/B9780323461436000178; http://linkinghub.elsevier.com/retrieve/pii/B9780323461436000178; http://api.elsevier.com/content/article/PII:B9780323461436000178?httpAccept=text/plain; http://api.elsevier.com/content/article/PII:B9780323461436000178?httpAccept=text/xml; https://dx.doi.org/10.1016/b978-0-323-46143-6.00017-8
Elsevier BV
Provide Feedback
Have ideas for a new metric? Would you like to see something else here?Let us know